Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
暂无分享,去创建一个
[1] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[2] M Hummel,et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance , 2015, Cancer Gene Therapy.
[3] Jeffrey W. Clark,et al. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] A. King,et al. Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions , 2013, PloS one.
[5] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[6] A. Yoshizawa,et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. , 2011, Anticancer research.
[7] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.
[8] Antonio Marchetti,et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[10] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[11] G. Bollag,et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer , 2016, Proceedings of the National Academy of Sciences of the United States of America.
[12] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[13] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[14] R. Doebele,et al. A framework for understanding and targeting residual disease in oncogene-driven solid cancers , 2016, Nature Medicine.
[15] L. Layfield,et al. Lack of BRAF Activating Mutations in Prostate Adenocarcinoma: A Study of 93 Cases , 2009, Applied immunohistochemistry & molecular morphology : AIMM.
[16] BRAF inhibitor activity in V600R metastatic melanoma--response. , 2013, European journal of cancer.
[17] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[18] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[19] C. Belani,et al. Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer , 2015, PloS one.
[20] Jeanne Shen,et al. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[21] N. Girard,et al. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. , 2016, Lung cancer.
[22] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[23] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[24] A. Bryce,et al. Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma , 2015, Cureus.
[25] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[26] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[27] D. Schadendorf,et al. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. , 2014, Chinese clinical oncology.
[28] L. Haydu,et al. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma , 2014, Melanoma research.
[29] M. Ladanyi,et al. Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[31] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[32] M. Ladanyi,et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium , 2015, Cancer.
[33] Sourav Bandyopadhyay,et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.
[34] E. Nexo,et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays , 2014, BMC Cancer.
[35] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[36] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[37] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[38] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[39] Bastien Cabarrou,et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Marius Ilie,et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.
[42] Jean Mosser,et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.
[43] V. Sondak,et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.
[44] I. Wistuba,et al. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. , 2015, The oncologist.
[45] N. Myall,et al. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. , 2016, Clinical Lung Cancer.
[46] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[47] Jeffrey W. Clark,et al. Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .
[48] T. Kohno,et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] B. Neyns,et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors , 2016, Journal of Translational Medicine.
[50] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[51] Tae Min Kim,et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[52] R. Dummer,et al. Ultraviolet A and photosensitivity during vemurafenib therapy. , 2012, The New England journal of medicine.
[53] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Utikal,et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.
[55] Anil Vachani,et al. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.
[56] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[57] Matthew Wongchenko,et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.
[58] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[59] D. English,et al. Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype , 2008, Cancer Epidemiology Biomarkers & Prevention.
[60] S. Welsh,et al. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.
[61] L. Decoster,et al. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib , 2016, Oncotarget.
[62] Kyung Chul Moon,et al. BRAF and KRAS mutations in prostatic adenocarcinoma , 2006, International journal of cancer.
[63] H. Sasaki,et al. Uncommon V599E BRAF mutations in Japanese patients with lung cancer. , 2006, The Journal of surgical research.
[64] G. Sauter,et al. Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. , 2010, Oncology letters.
[65] Tae Min Kim,et al. An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer , 2016 .
[66] A. Gemma,et al. F1000 highlights , 2010 .
[67] J. Gray,et al. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. , 2015, Cancer genetics.
[68] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.